Key result
ERG shows 100% sensitivity for hepatic angiosarcoma, outperforming CD34, CD31, and FVIIIRAg.
Why the study?
Is ERG a more sensitive diagnostic marker for hepatic angiosarcoma compared to CD31, CD34, and FVIIIRAg?
Cohort (n=24)
No
Is ERG a more sensitive diagnostic marker for hepatic angiosarcoma compared to CD31, CD34, and FVIIIRAg?
ERG is a highly sensitive diagnostic marker for hepatic angiosarcoma, outperforming traditional markers like CD31, CD34, and FVIIIRAg.
No takes yet. Share an insight, caveat, or question.
ERG may aid hepatic angiosarcoma diagnosis; Level 5 case data leaves open prospective validation.
Zhanbo Wang (2014) conducted a cohort in Hepatic angiosarcoma (n=24). ERG vs. CD31, CD34, and FVIIIRAg was evaluated on Marker expression positivity. ERG was expressed in 100% of hepatic angiosarcoma samples, making it a more sensitive diagnostic marker than CD34 (87.5%), CD31 (79.2%), and FVIIIRAg (41.7%).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: